Sandoz, a global leader in generic and biosimilar medicines, announced that the European Commission (EC) granted marketing authorization for the first and only biosimilar Tyruko® (natalizumab), developed by Polpharma Biologics. The European approval for Tyruko comes a month after…

  Italian company Alfasigma has signed a definitive agreement for the acquisition of all issued and outstanding shares in Intercept Pharmaceuticals. Alfasigma will pay $19 for each share of Intercept. The acquisition will help boost Alfasigma’s gastroenterology and hepatology pipeline,…